Comments to the ACC/AHA/ESC guidelines for the prevention of arterial thrombolism in patients with atrial fibrillation;Kommentar zu den ACC/AHA/ESC-leitlinien 2001 zur prävention arterieller thromboembolien bei patienten mit vorhofflimmern

Zeitschrift fur Kardiologie

Volumn 92, Issue 8, 2003, Pages 694-703

  Schuchert, Andreas ^a   Gulba, Dietrich ^b   Horstkotte, Dieter H ^c   Meinertz, Thomas ^a   Tebbe, Ulrich ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Krankenhaus Duren gem GmbH   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d KLINIKUM LIPPE DETMOLD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVERSION; EVIDENCE BASED MEDICINE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; NOTE; PRACTICE GUIDELINE; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT INDICATION;

EID: 0041323079     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-0992-6     Document Type: Note

References (67)

1. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus Aspirin for high-risk patients with atrial fibrillation (1996) Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348:633-638
2. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer D (2001) Antithrombic therapy in atrial fibrillation. Chest 119:S194-S206
3. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457
4. Atrial Fibrillation Investigators (1997) The efficacy of Aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 157:1237-1240
5. Atrial Fibrillation Investigators (1998) Echocardiographic predictors of stroke in patients with atrial fibrillation a prospective study of 1,066 patients from three clinical trials. Arch Intern Med 158:1316-1320
6. Bar-Sela S, Ehrenfeld M, Eliakim M (1981) Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 141:1191-1192
7. Berger M, Schweitzer P (1998) Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 82:1545-1547
8. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA (2001) Risk of stroke in patients with atrial flutter. Am J Cardiol 87:346-349, A9
9. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323:1505-1511
10. Collins LJ, Silverman DI, Douglas PS et al (1995) Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 92:160-163
11. Connolly SJ, Laupacis A, Gent M et al (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18:349-355
12. EAFT (European Atrial Fibrillation Trial Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
13. European Atrial Fibrillation Trial Study Group (1995) Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333:5-10
14. Evans A, Kalra L (2001) Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 161:1443-1447
15. Ezekowitz MD, Bridgers SL, James KE et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406-1412
16. Ezekowitz MD, James KE, Nazarian SM (1995) Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 92:2178-2182
17. Feinberg WM, Blackshear JL, Laupacis A (1995) The prevalence of atrial fibrillation: analysis and implications. Arch Intern Med 155:469-473
18. Fihn SD, Callahan CM, Martin DC for the National Consortium of Anticoagulation Clinics (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124:970-979
19. Furberg CD, Psaty BM, Manolio TA (1994) Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 74:238-241
20. Fuster V, Ryden LE (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. JACC 38:1231-1266
21. Gallagher MM, Camm J (1997) Classification of atrial fibrillation. PACE 20:1603-1605
22. Gorter JW, for the Stroke Prevention In Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) study groups (1999) Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 53:1319-1327
23. Gullov AL, Koefoed BG, Petersen P (1998) Fixed minidose warfarin and Aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (the AFASAK-2 study). Arch Intern Med 158:1513-1521
24. Gullov AL, Koefoed BG, Petersen P (1999) Bleeding during warfarin and Aspirin therapy in patients with atrial fibrillation: the AFASAK-2 Study. Arch Intern Med 159:1322-1328
25. Hart RG, Benavente O, McBride R (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492-501
26. Hart RG, Benavente O, Pearce LA (1999) Increased risk of intracranial hemorrhage when Aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 9:215-217
27. Hart RG, Pearce LA, McBride R et al (1999) Factors associated with ischemic stroke during Aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30:1223-1229
28. Hart RG, Pearce LA, Rothbart RM et al (2000) Stroke with intermittent atrial fibrillation: incidence and predictors during Aspirin therapy. J Am Coll Cardiol 35:183-187
29. Hellemons BSP, Lanbenberg M, Lodder J et al (1999) Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with Aspirin. BMJ 319:958-964
30. Hirsh J, Warkentin TE, Shaughnessy SG et al (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:S64-S94
31. Howitt A, Armstrong D (1999) Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 318:1324-1327
32. Hurley DM, Hunter AN, Hewett MJ et al (1981) Atrial fibrillation and arterial embolism in hyperthyroidism. Aust NZ J Med 11:391-393
33. Hylek EM, Skates SJ, Sheehan MA et al (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
34. Klein AL, Grimm RA, Murray RD et al (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411-1420
35. Körtke H, Gohlke-Bärwolf C, Heik SCW, Horstkotte D, Körfer R (1998) Empfehlungen zum INR-Selbstmanagement bei oraler Antikoagulation. Z Kardiol 87:983-985
36. Lake FR, McCall MG, Cullen KJ et al (1989) Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 19:321-326
37. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152
38. Lanzarotti CJ, Olshansky B (1997) Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 30:1506-1511
39. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE (1998) Antithrombotic therapy in atrial fibrillation. Chest 114:S579-S589
40. Marine JE, Goldhaber SZ (1998) Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest 113:1115-1118
41. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC, for the Stroke Prevention in Atrial Fibrillation Investigators (1993) Ischemic stroke in patients with atrial fibrillation: effect of Aspirin according to stroke mechanism. Neurology 43:32-36
42. Mitchell MA, Hughes GS, Ellenbogen KE et al (1997) Cardioversion-related stroke rates in atrial fibrillation and atrial flutter. Circulation 96:I-453
43. Pearce LA, Hart RG, Halperin JL (2000) Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 109:45-51
44. Pengo V, Zasso A, Barbero F et al (1998) Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 82:433-437
45. Petersen P, Hansen JM (1988) Stroke in thyrotoxicosis with atrial fibrillation. Stroke 19:15-18
46. Petersen P, Boysen G, Godtfredsen J et al (1989) Placebo-controlled, randomised trial of warfarin and Aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1:175-178
47. Phillips SJ, Whisnant JP, O'Fallon WM et al (1990) Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc 65:344-359, S204
48. Presti CF, Hart RG (1989) Thyrotoxicosis, atrial fibrillation, and embolism revisited. Am Heart J 117:976-977
49. Seidl K, Hauer B, Schwick NG et al (1998) Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 82:580-583
50. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators (1998) Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with Aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 279:1273-1277
51. Staffurth JS, Gibberd MC, Ng Tang Fui S (1977) Arterial embolism in thyrotoxicosis with atrial fibrillation. BMJ 2:688-690
52. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG (2001) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119:S 220-S 227
53. Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kuhle K, Fetsch T, Greve R, Schmidt-Lucke JA (2002) Low molecular weight heparin for prevention of thromboembolic complications in cardioversion - rationale and design of the Ace study (Anticoagulation in Cardioversion using Enoxaparin). Z Kardiol 91:249-254
54. Stollberger C, Chnupa P, Kronik G et al (1998) Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 128:630-638
55. Stroke Prevention in Atrial Fibrillation Investigators (1991) Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 84:527-539
56. Stroke Prevention in Atrial Fibrillation Investigators (1992) Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 116:1-5
57. Stroke Prevention in Atrial Fibrillation Investigators (1992) Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 116:6-12
58. Stroke Prevention in Atrial Fibrillation Investigators (1994) Warfarin versus Aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687-691
59. Stroke Prevention in Atrial Fibrillation Investigators (1995) Risk factors for thromboembolism during Aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Defibrillation Study. J Stroke Cerebrovasc Dis 5:147-157
60. Stroke Prevention in Atrial Fibrillation Investigators (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156:409-416
61. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography (1998) Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 128:639-647
62. Taylor FC, Cohen H, Ebrahim S (2001) Systematic review of long-term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 322:321-326
63. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus Aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865
64. Weigner MJ, Caulfield TA, Danias PG et al (1997) Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 126:615-620
65. Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 147:1561-1564
66. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983-988
67. Yuen RWM, Gutteridge DH, Thompson PL et al (1979) Embolism in thyrotoxic atrial fibrillation. Med J Aust 1:630-631